Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer

NCT02578797 is registered in ClinicalTrials.gov with Aragon Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02578797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02578797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer
Lead sponsor
Aragon Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 18, 2015
Completion date
October 13, 2022
Enrollment
45 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer